Cargando…
Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study
AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting....
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668059/ https://www.ncbi.nlm.nih.gov/pubmed/34022121 http://dx.doi.org/10.1111/jdi.13598 |
_version_ | 1784614490167312384 |
---|---|
author | Kuwata, Hitoshi Yabe, Daisuke Murotani, Kenta Fujiwara, Yuuka Haraguchi, Takuya Kubota, Sodai Kubota‐Okamoto, Saki Usui, Ryota Ishitobi, Minori Yamazaki, Yuji Hamamoto, Yoshiyuki Kurose, Takeshi Seino, Yusuke Yamada, Yuichiro Seino, Yutaka |
author_facet | Kuwata, Hitoshi Yabe, Daisuke Murotani, Kenta Fujiwara, Yuuka Haraguchi, Takuya Kubota, Sodai Kubota‐Okamoto, Saki Usui, Ryota Ishitobi, Minori Yamazaki, Yuji Hamamoto, Yoshiyuki Kurose, Takeshi Seino, Yusuke Yamada, Yuichiro Seino, Yutaka |
author_sort | Kuwata, Hitoshi |
collection | PubMed |
description | AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. MATERIALS AND METHODS: A single‐arm, prospective, observational study was conducted to evaluate the effects of various GLP‐1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP‐1RA initiation. Effects on postprandial secretions of glucose‐dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. RESULTS: Eighteen subjects with type 2 diabetes received one of three GLP‐1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12‐week administration of all of the GLP‐1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP‐1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP‐1RAs. CONCLUSIONS: All of the GLP‐1RAs were found to improve HbA1c in a 12‐week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose‐lowering effects and body weight reduction were observed. |
format | Online Article Text |
id | pubmed-8668059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86680592021-12-21 Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study Kuwata, Hitoshi Yabe, Daisuke Murotani, Kenta Fujiwara, Yuuka Haraguchi, Takuya Kubota, Sodai Kubota‐Okamoto, Saki Usui, Ryota Ishitobi, Minori Yamazaki, Yuji Hamamoto, Yoshiyuki Kurose, Takeshi Seino, Yusuke Yamada, Yuichiro Seino, Yutaka J Diabetes Investig Articles AIMS/INTRODUCTION: Differences in the glucose‐lowering mechanisms of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting. MATERIALS AND METHODS: A single‐arm, prospective, observational study was conducted to evaluate the effects of various GLP‐1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP‐1RA initiation. Effects on postprandial secretions of glucose‐dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated. RESULTS: Eighteen subjects with type 2 diabetes received one of three GLP‐1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12‐week administration of all of the GLP‐1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP‐1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP‐1RAs. CONCLUSIONS: All of the GLP‐1RAs were found to improve HbA1c in a 12‐week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose‐lowering effects and body weight reduction were observed. John Wiley and Sons Inc. 2021-06-16 2021-12 /pmc/articles/PMC8668059/ /pubmed/34022121 http://dx.doi.org/10.1111/jdi.13598 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Kuwata, Hitoshi Yabe, Daisuke Murotani, Kenta Fujiwara, Yuuka Haraguchi, Takuya Kubota, Sodai Kubota‐Okamoto, Saki Usui, Ryota Ishitobi, Minori Yamazaki, Yuji Hamamoto, Yoshiyuki Kurose, Takeshi Seino, Yusuke Yamada, Yuichiro Seino, Yutaka Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study |
title | Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study |
title_full | Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study |
title_fullStr | Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study |
title_full_unstemmed | Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study |
title_short | Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study |
title_sort | effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in japanese individuals with type 2 diabetes: a prospective, observational study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668059/ https://www.ncbi.nlm.nih.gov/pubmed/34022121 http://dx.doi.org/10.1111/jdi.13598 |
work_keys_str_mv | AT kuwatahitoshi effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT yabedaisuke effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT murotanikenta effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT fujiwarayuuka effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT haraguchitakuya effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT kubotasodai effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT kubotaokamotosaki effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT usuiryota effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT ishitobiminori effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT yamazakiyuji effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT hamamotoyoshiyuki effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT kurosetakeshi effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT seinoyusuke effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT yamadayuichiro effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy AT seinoyutaka effectsofglucagonlikepeptide1receptoragonistsonsecretionsofinsulinandglucagonandgastricemptyinginjapaneseindividualswithtype2diabetesaprospectiveobservationalstudy |